Sarah M. Baxter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sarah M. Baxter has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Anna Gavin
Centre for Public Health, Queen’s University Belfast, Belfast, Northern Ireland, UK
3 shared publicationsCharlene M. McShane
Centre for Public Health, Queen’s University Belfast, Belfast, Northern Ireland, UK
3 shared publicationsChris R. Cardwell
Centre for Public Health, Queen’s University Belfast, Belfast, Northern Ireland, UK
3 shared publicationsDamien Bennett
Centre for Public Health, Queen’s University Belfast, Belfast, Northern Ireland, UK
3 shared publicationsDavid McCallion
Patient representative, England, UK
3 shared publicationsDeirdre Fitzpatrick
Northern Ireland Cancer Registry, Belfast, UK
3 shared publications
Latest Publications
- Open Access
- 21 March 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 216 (3) , 33
House value as an individual socioeconomic indicator for breast cancer survival and late-stage diagnosis: a population-based cohort study from Northern Ireland
Purpose: Socioeconomic inequalities in breast cancer survival persist in the UK. Area-based deprivation measures may underestimate socioeconomic effects by assigning average deprivation levels to all area inhabitants. This study investigated associations between house value (individual-level) and area-based deprivation with breast cancer outcomes in Northern Ireland. Methods: Women diagnosed with breast cancer from 2011 to 2021 were identified using the Northern Ireland Cancer Registry. House value was determined from Valuation and Lands Agency property valuation data, and area-based deprivation from the Northern Ireland Multiple Deprivation Measure. The primary outcome was breast cancer-specific mortality. Secondary outcomes were stage at diagnosis and all-cause mortality. Cox regression models calculated adjusted hazard ratios (HR) and 95% confidence intervals (95% CIs) for mortality by house value category and deprivation, adjusting for confounders. Results: Among 12,766 women with breast cancer, women in the lowest versus highest house value category had a 60% increase in mortality (adjusted HR = 1.60 95% CI 1.34, 1.92; per 20 percentile decrease adjusted HR = 1.12 95% CI 1.08, 1.16) and were more likely diagnosed with stage 4 disease (7.5% versus 4.1%; P < 0.001). Women living in the most versus least deprived areas had a 26% increase in mortality (adjusted HR = 1.26 95% CI 1.08, 1.47; per 20 percentile decrease adjusted HR = 1.05 95% CI 1.01, 1.08) but had no difference in stage 4 disease (5.9% vs. 5.0%; P = 0.157). Conclusion: Individual-level house value demonstrated stronger associations with breast cancer outcomes than area-level deprivation, suggesting it may serve as a more sensitive indicator for monitoring health inequalities in cancer.
- 21 March 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 216 (3) , 33
Open AccessHouse value as an individual socioeconomic indicator for breast cancer survival and late-stage diagnosis: a population-based cohort study from Northern Ireland
Purpose: Socioeconomic inequalities in breast cancer survival persist in the UK. Area-based deprivation measures may underestimate socioeconomic effects by assigning average deprivation levels to all area inhabitants. This study investigated associations between house value (individual-level) and area-based deprivation with breast cancer outcomes in Northern Ireland. Methods: Women diagnosed with breast cancer from 2011 to 2021 were identified using the Northern Ireland Cancer Registry. House value was determined from Valuation and Lands Agency property valuation data, and area-based deprivation from the Northern Ireland Multiple Deprivation Measure. The primary outcome was breast cancer-specific mortality. Secondary outcomes were stage at diagnosis and all-cause mortality. Cox regression models calculated adjusted hazard ratios (HR) and 95% confidence intervals (95% CIs) for mortality by house value category and deprivation, adjusting for confounders. Results: Among 12,766 women with breast cancer, women in the lowest versus highest house value category had a 60% increase in mortality (adjusted HR = 1.60 95% CI 1.34, 1.92; per 20 percentile decrease adjusted HR = 1.12 95% CI 1.08, 1.16) and were more likely diagnosed with stage 4 disease (7.5% versus 4.1%; P < 0.001). Women living in the most versus least deprived areas had a 26% increase in mortality (adjusted HR = 1.26 95% CI 1.08, 1.47; per 20 percentile decrease adjusted HR = 1.05 95% CI 1.01, 1.08) but had no difference in stage 4 disease (5.9% vs. 5.0%; P = 0.157). Conclusion: Individual-level house value demonstrated stronger associations with breast cancer outcomes than area-level deprivation, suggesting it may serve as a more sensitive indicator for monitoring health inequalities in cancer.
- Open Access
- 21 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Antibiotic use and survival from breast cancer: A population-based cohort study in England and Wales
The role of the gut microbiota in carcinogenesis is increasingly being acknowledged. Recent studies in multiple breast cancer mouse models have found that antibiotics, by altering the gut microbiota, can accelerate tumour growth. In humans, a recent cohort study restricted to triple negative breast cancer showed that breast cancer patients using a greater number of antibiotics had markedly worse survival. These studies have raised concerns about repeated antibiotic use in breast cancer patients. In this Registered Report, we investigated whether breast cancer patients using oral antibiotics had increased breast cancer-specific mortality. In population-based cohorts (n = 44,452), we did not observe a statistically significant association between antibiotic prescriptions after diagnosis and breast cancer-specific mortality (adjusted HR = 1.07 95% CI 0.87, 1.33) apart from prescriptions of 12 or more antibiotics (adjusted HR = 1.62 95% CI 1.31, 2.01). This association was weaker after adjustment for infections (adjusted HR = 1.44 95% 1.14, 1.81), when restricted to antibiotics within five years (adjusted HR = 1.33 95% 0.95, 1.84), and was similar for deaths from other causes (adjusted HR = 1.69 95% 1.19, 2.41). Frequent antibiotic users had higher cancer-specific mortality but the attenuation of associations in sensitivity analyses, and similar findings for other causes of death, suggest this increase may reflect residual confounding. Protocol registration: The Stage 1 protocol for this Registered Report was accepted in principle on 7 November 2023. The protocol, as accepted by the journal, can be found at https://doi.org/10.6084/m9.figshare.24746721.v1 .
- 21 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Open AccessAntibiotic use and survival from breast cancer: A population-based cohort study in England and Wales
The role of the gut microbiota in carcinogenesis is increasingly being acknowledged. Recent studies in multiple breast cancer mouse models have found that antibiotics, by altering the gut microbiota, can accelerate tumour growth. In humans, a recent cohort study restricted to triple negative breast cancer showed that breast cancer patients using a greater number of antibiotics had markedly worse survival. These studies have raised concerns about repeated antibiotic use in breast cancer patients. In this Registered Report, we investigated whether breast cancer patients using oral antibiotics had increased breast cancer-specific mortality. In population-based cohorts (n = 44,452), we did not observe a statistically significant association between antibiotic prescriptions after diagnosis and breast cancer-specific mortality (adjusted HR = 1.07 95% CI 0.87, 1.33) apart from prescriptions of 12 or more antibiotics (adjusted HR = 1.62 95% CI 1.31, 2.01). This association was weaker after adjustment for infections (adjusted HR = 1.44 95% 1.14, 1.81), when restricted to antibiotics within five years (adjusted HR = 1.33 95% 0.95, 1.84), and was similar for deaths from other causes (adjusted HR = 1.69 95% 1.19, 2.41). Frequent antibiotic users had higher cancer-specific mortality but the attenuation of associations in sensitivity analyses, and similar findings for other causes of death, suggest this increase may reflect residual confounding. Protocol registration: The Stage 1 protocol for this Registered Report was accepted in principle on 7 November 2023. The protocol, as accepted by the journal, can be found at https://doi.org/10.6084/m9.figshare.24746721.v1 .
- Open Access
House value as an individual socioeconomic indicator for breast cancer survival and late-stage diagnosis: a population-based cohort study from Northern Ireland
Background: Socio-economic inequalities in breast cancer survival persist globally, including in the UK. Area-based deprivation measures may underestimate true socio-economic effects by assigning average levels to all individuals within an area. This study investigated associations between house value (individual-level socio-economic indicator) and area-based deprivation with breast cancer outcomes in Northern Ireland. Methods: Women diagnosed with breast cancer 2011 to 2021 were identified using the Northern Ireland Cancer Registry. House value was determined from Valuation and Lands Agency property valuation data, and area-based deprivation was determined from the Northern Ireland Multiple Deprivation Measure. The primary outcome was breast cancer-specific mortality. Secondary outcomes included stage at diagnosis. Cox regression models calculated adjusted hazard ratios (HR) and (95%CIs) for cancer-specific mortality by house value category and separately for deprivation, adjusting for confounders. Results: Among 12,766 women with breast cancer, associations were much more pronounced for house value than area-based deprivation. Women in the lowest house value category, compared to the highest value category, had a 60% increase in mortality (adjusted HR=1.60 95%CI 1.34, 1.92) and were more likely to be diagnosed with stage 4 disease (7.5% versus 4.1%; P<0.001). Women living in the most versus least deprived areas had a 26% increase in mortality (adjusted HR=1.26 95%CI 1.08, 1.47) and were more likely to be diagnosed with stage 4 disease (5.9% vs 5.0%; P =0.157). Conclusion: House value demonstrated stronger associations with breast cancer outcomes than area-level deprivation, suggesting it may serve as a more sensitive indicator for monitoring health inequalities in cancer. What is already known: Lower socioeconomic status is associated with worse breast cancer survival in the UK and internationally. Area-based measures of deprivation are widely used in epidemiological research but have recognised limitations. What this study adds: We observed socio-economic gradients for both late-stage at diagnosis and breast cancer survival for both house value and area-deprivation. However, associations were stronger for house value and effects persisted after adjustment for area deprivation. How this might affect research, policy and practice: Our findings establish that publicly available property valuations provide a feasible and sensitive measure for monitoring socioeconomic health inequalities at the population level
Open AccessHouse value as an individual socioeconomic indicator for breast cancer survival and late-stage diagnosis: a population-based cohort study from Northern Ireland
Background: Socio-economic inequalities in breast cancer survival persist globally, including in the UK. Area-based deprivation measures may underestimate true socio-economic effects by assigning average levels to all individuals within an area. This study investigated associations between house value (individual-level socio-economic indicator) and area-based deprivation with breast cancer outcomes in Northern Ireland. Methods: Women diagnosed with breast cancer 2011 to 2021 were identified using the Northern Ireland Cancer Registry. House value was determined from Valuation and Lands Agency property valuation data, and area-based deprivation was determined from the Northern Ireland Multiple Deprivation Measure. The primary outcome was breast cancer-specific mortality. Secondary outcomes included stage at diagnosis. Cox regression models calculated adjusted hazard ratios (HR) and (95%CIs) for cancer-specific mortality by house value category and separately for deprivation, adjusting for confounders. Results: Among 12,766 women with breast cancer, associations were much more pronounced for house value than area-based deprivation. Women in the lowest house value category, compared to the highest value category, had a 60% increase in mortality (adjusted HR=1.60 95%CI 1.34, 1.92) and were more likely to be diagnosed with stage 4 disease (7.5% versus 4.1%; P<0.001). Women living in the most versus least deprived areas had a 26% increase in mortality (adjusted HR=1.26 95%CI 1.08, 1.47) and were more likely to be diagnosed with stage 4 disease (5.9% vs 5.0%; P =0.157). Conclusion: House value demonstrated stronger associations with breast cancer outcomes than area-level deprivation, suggesting it may serve as a more sensitive indicator for monitoring health inequalities in cancer. What is already known: Lower socioeconomic status is associated with worse breast cancer survival in the UK and internationally. Area-based measures of deprivation are widely used in epidemiological research but have recognised limitations. What this study adds: We observed socio-economic gradients for both late-stage at diagnosis and breast cancer survival for both house value and area-deprivation. However, associations were stronger for house value and effects persisted after adjustment for area deprivation. How this might affect research, policy and practice: Our findings establish that publicly available property valuations provide a feasible and sensitive measure for monitoring socioeconomic health inequalities at the population level
- Open Access
- 5 July 2025
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 213 (1) , 137-150
Stage at diagnosis and breast cancer-specific mortality in breast cancer patients treated with antidepressants, anxiolytics, and antipsychotics: a population-based cohort study from Northern Ireland
Purpose: We examined the stage at diagnosis and breast cancer-specific mortality in a cohort of breast cancer patients prescribed medications used for mental health conditions before diagnosis. Methods: Women newly diagnosed with breast cancer from 2011 to 2021 were identified from the Northern Ireland Cancer Registry. The primary outcome was time to breast cancer-specific mortality up to March 2023. The secondary outcomes included stage at diagnosis. We identified anxiolytic, antidepressant, and antipsychotic prescriptions dispensed in the year before breast cancer diagnosis from the Northern Ireland Enhanced Prescribing Database. Cox regression models were used to calculate adjusted hazard ratios (aHR) and 95% confidence intervals (95%CIs) for cancer-specific mortality by use of medications. Results: We included 13,846 women with breast cancer. In the year before breast cancer diagnosis, 31.5% were dispensed antidepressants, 12.7% anxiolytics, and 3.5% antipsychotics. The odds of late-stage disease presentation in breast cancer patients dispensed medications for mental health conditions was similar to breast cancer patients not dispensed these medications, but patients dispensed antipsychotics had higher odds of unknown stage. We found no difference in the hazard rate of breast cancer-specific mortality in patients dispensed, versus not dispensed, anxiolytics (aHR = 1.06 95%CI 0.93–1.20), a small increase in patients dispensed, versus not dispensed, antidepressants (aHR = 1.11 95%CI 1.01–1.23) and a moderate increase in patients dispensed, versus not dispensed, antipsychotics (aHR = 1.45 95%CI 1.17–1.81). Conclusions: Breast cancer patients dispensed medications for mental health conditions were not at higher odds of presenting with late-stage disease, but patients dispensed antidepressants, and especially antipsychotics, had worse breast cancer-specific mortality.
- 5 July 2025
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 213 (1) , 137-150
Open AccessStage at diagnosis and breast cancer-specific mortality in breast cancer patients treated with antidepressants, anxiolytics, and antipsychotics: a population-based cohort study from Northern Ireland
Purpose: We examined the stage at diagnosis and breast cancer-specific mortality in a cohort of breast cancer patients prescribed medications used for mental health conditions before diagnosis. Methods: Women newly diagnosed with breast cancer from 2011 to 2021 were identified from the Northern Ireland Cancer Registry. The primary outcome was time to breast cancer-specific mortality up to March 2023. The secondary outcomes included stage at diagnosis. We identified anxiolytic, antidepressant, and antipsychotic prescriptions dispensed in the year before breast cancer diagnosis from the Northern Ireland Enhanced Prescribing Database. Cox regression models were used to calculate adjusted hazard ratios (aHR) and 95% confidence intervals (95%CIs) for cancer-specific mortality by use of medications. Results: We included 13,846 women with breast cancer. In the year before breast cancer diagnosis, 31.5% were dispensed antidepressants, 12.7% anxiolytics, and 3.5% antipsychotics. The odds of late-stage disease presentation in breast cancer patients dispensed medications for mental health conditions was similar to breast cancer patients not dispensed these medications, but patients dispensed antipsychotics had higher odds of unknown stage. We found no difference in the hazard rate of breast cancer-specific mortality in patients dispensed, versus not dispensed, anxiolytics (aHR = 1.06 95%CI 0.93–1.20), a small increase in patients dispensed, versus not dispensed, antidepressants (aHR = 1.11 95%CI 1.01–1.23) and a moderate increase in patients dispensed, versus not dispensed, antipsychotics (aHR = 1.45 95%CI 1.17–1.81). Conclusions: Breast cancer patients dispensed medications for mental health conditions were not at higher odds of presenting with late-stage disease, but patients dispensed antidepressants, and especially antipsychotics, had worse breast cancer-specific mortality.